A Prospective, Open, Single-arm, Single Center, Phase II Trial to Assess the Efficacy of Anti-PD1 Antibody in Combination With Pulsed Hedgehog Inhibitor in Advanced Basal Cell Carcinoma
Latest Information Update: 01 Aug 2024
Price :
$35 *
At a glance
- Drugs Cemiplimab (Primary) ; Sonidegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 30 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2021 Study design released at the 46th European Society for Medical Oncology Congress
- 17 Mar 2021 Status changed from not yet recruiting to recruiting.